drugset / Trial / NCT02446028

A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes

NCT02446028

Phase 2 Suspended 13 enrolled Biodel
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of BIOD-531 compared to Humalog®Mix 75/25 in patients with type 2 diabetes.

Timeline

Start
2015-05
Primary completion
2016-02
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BIOD-531 Protein / enzyme biologic
Comparator Humalog®Mix 75/25 Protein / enzyme biologic